GeneDx Holdings (WGS) Depreciation & Amortization (CF) (2020 - 2022)

GeneDx Holdings (WGS) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $5.8 million the latest figure, recorded in Q1 2022.

• On a quarterly basis, Depreciation & Amortization (CF) rose 18.38% year-over-year to $5.8 million in Q1 2022; TTM through Dec 2022 was $5.8 million, a 64.17% decrease from a year earlier, with the FY2022 full-year figure at $59.3 million, up 171.97% from the prior year.
• Depreciation & Amortization (CF) was $5.8 million for Q1 2022 at GeneDx Holdings, roughly flat from $5.8 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.8 million in Q1 2022 and troughed at $3.1 million in Q3 2020.
• A 3-year average of $4.8 million and a median of $5.2 million in 2021 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 77.42% in 2021 and rose 18.38% in 2022, its largest moves.
• Over 3 years, Depreciation & Amortization (CF) stood at $3.6 million in 2020, then surged by 61.56% to $5.8 million in 2021, then rose by 0.14% to $5.8 million in 2022.
• The last three Depreciation & Amortization (CF) figures came in at $5.8 million (Q1 2022), $5.8 million (Q4 2021), and $5.5 million (Q3 2021), per Business Quant data.